GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2011

BioFocus to Offer Screening and Profiling Services Based on Almac’s Flexyte FLT Platform

  • BioFocus and Almac have inked an agreement that will allow BioFocus to offer its customers compound screening and profiling services using Almac’s Flexyte™ fluorescence lifetime (FLT) assays. The firm has launched an FLT screening and profiling service using the Flexyte platform, for targets including proteases, phosphatases, and kinases. It says the Flexyte platform can be exploited for applications including fragment-based screens and kinetic profiling.

    “Being able to incorporate FLT in our service offering enables BioFocus to provide clients with an approach to screening and profiling that will unlock significant potential within their drug discovery efforts,” comments Kate Hilyard, vp biological sciences.

    Almac claims the Flexyte approach harnesses fluorescence lifetime technology that negates the need for radioactivity and antibodies, to enable robust and reliable assays that can be miniaturized and multiplexed.  


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?